Model-Based Evaluation of the Efficacy and Safety of Burosumab, A Fully Human Anti-FGF23 Monoclonal Antibody, In Adolescent X-Linked Hypophosphatemia (XLH)
May 1, 2018, 00:00
10.1016/j.jval.2018.04.1669
https://www.valueinhealthjournal.com/article/S1098-3015(18)31991-0/fulltext
Title :
Model-Based Evaluation of the Efficacy and Safety of Burosumab, A Fully Human Anti-FGF23 Monoclonal Antibody, In Adolescent X-Linked Hypophosphatemia (XLH)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31991-0&doi=10.1016/j.jval.2018.04.1669
First page :
Section Title :
Open access? :
No
Section Order :
887